SCHEMBL8979322

SCHEMBL8979322

CNN(C)c1cccc(C)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.46
SIGMAR1 Q99720 1/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
HSD17B1 P14061 3/20 0.40
HSD17B2 P37059 3/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
NPC1 O15118 1/20 0.39
NSD2 O96028 1/20 0.39
CASP3 P42574 1/20 0.39
RAB9A P51151 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
CSF1R P07333 3/20 0.39
EGFR P00533 2/20 0.38
THRB P10828 1/20 0.38
PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11251562 0.80 ACHE (0.48) ACHESIGMAR1SLC6A2SLC6A4HSD17B1
SCHEMBL23601312 0.79 HSD17B1 (0.42) HSD17B1HSD17B2NPC1RAB9AALDH1A1
SCHEMBL9033002 0.77 ALDH1A1 (0.34) NPC1RAB9AALDH1A1CYP3A4MAPT
SCHEMBL28021366 0.77 ALDH1A1 (0.63) ACHEHSD17B1HSD17B2TDP1RAB9A
SCHEMBL8979210 0.77 HTR3E (0.50) SLC6A2SLC6A4MEN1KMT2ATDP1
SCHEMBL8979321 0.77 ACHE (0.41) ACHESLC6A2SLC6A4KMT2ANPC1
SCHEMBL12879 0.77 ALDH1A1 (0.56) ACHESIGMAR1HSD17B1HSD17B2MEN1
SCHEMBL29381010 0.77 ALDH1A1 (0.56) ACHESIGMAR1HSD17B1HSD17B2MEN1
SCHEMBL1697445 0.77 ACHE (0.55) ACHESIGMAR1HSD17B1HSD17B2MEN1
SCHEMBL21065746 0.75 ALDH1A1 (0.54) ACHESIGMAR1HSD17B1HSD17B2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188097-B2 Pyrazolo[1,5-A]pyrimidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US disclosed
US-8188097-B2 Pyrazolo[1,5-A]pyrimidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US disclosed
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds TANABE SEIYAKU CO., LTD. (JP) 2009-03-12 US disclosed
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds TANABE SEIYAKU CO., LTD. (JP) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds RECQL, QTRT1, DPYD ACHE 3511/4885SIGMAR1 592/4885SLC6A2 3051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.